Clinical Study On Dahuang And Zhechong Pills Combined With Entecavir In Treating Hepatitis B Cirrhosis Of Blood-stasis Obstructing Type

Objective: By comparing the clinical efficacy of Dahuang and Zhechong pills combined with Entecavir and Entecavir alone in treating decompensated Hepatitis B cirrhosis of blood-stasis obstructing type,we try to evaluate the clinical efficacy scientifically and objectively,and to explore a safe and practical scheme of treatment combined with traditional Chinese and western medicine in treating Hepatitis B cirrhosis,and to delay the process of cirrhosis,then provide evidence for therapeutic schemes in treatment combined with traditional Chinese and western medicine in treating Hepatitis B cirrhosis.Methods: 60 cases of patients diagnosed with decompensated Hepatitis B cirrhosis of blood-stasis obstructing type were randomly divided into two groups,30 cases in each group.All the patients were selected in the liver disease department of inpatients and outpatiens treated in the First Affiliate Hospital of Guangxi University of Chinese Medicine during September 2016 to July 2017.Patients in the treatment group were given Entecavir dispersible tables(7:30 in the morning with an oral dose,0.5mg/day)combined with Dahuang and Zhechong pills(3g/ pills,12g/day,early and late 8:00),while patients in the control group were given a simple Entecavir dispersible tables treatment.Both groups' were treated for 24 weeks,and 12 weeks in each period.Before and after the treatment,observed and compare the patients' s traditional Chinese medicine(TCM)syndrome integral,liver function(AST?ALT),the platelet count(PLT),the aspartate aminotrans ferase-to-platelet ratio index(APRI),liver stiffness measurement(LSM),the portal venous diameter,the thickness of spleen and safety indicators were recorded.After observation,statistical analysis was conducted to evaluate the efficacy of the two groups.Results:1)Total after effective rate: the effective rate of treatment group was 86.67%,while the control group was 66.67%,the effective rate of the treatment group was higher than the control group,the difference was statistically significant(P<0.05).2)liver stiffness measurement(LSM): when treated for 12 weeks and 24 weeks,the improvement of LSM in treatment group was better than the same group after the treatment,the difference was statistically significant(P<0.05);when treated for 12 weeks,the improvement of LSM in control group was similar to the same group after the treatment,the difference was not statistically significant(P>0.05);when treated for 24 weeks,the improvement of LSM in control group was better than the same group after the treatment,the difference was statistically significant(P<0.05).When treated for 12 weeks and 24 weeks,the improvement of LSM in treatment group was better than that in control group,the difference was statistically significant(P<0.05).3)Portal venous diameter and spleen thickness: when treated for 12 weeks and 24 weeks,the portal venous diameter and spleen thickness in treatment group was smaller than that in control group,the difference was statistically significant(P<0.05).When treated for 12 weeks,the improvement of portal venous diameter and spleen thickness in treatment group was similar to the control group,the difference was not statistically significant(P>0.05);when treated for 24 weeks,the portal venous diameter and spleen thickness in treatment group was smaller than that in control group,the difference was statistically significant(P<0.05).4)PLT and APRI: when treated for 12 weeks,the improvement of PLT and APRI in treatment group and control group was similar to the same group after the treatment,the difference was not statistically significant(P>0.05);the improvement of PLT and APRI in treatment group was similar to the control group,the difference was not statistically significant(P>0.05).When treated for 24 weeks,the improvement of PLT and APRI in treatment group and control group was better than the same group after thetreatment,the difference was statistically significant(P<0.05);the improvement of PLT and APRI in treatment group was better than control group,the difference was statistically significant(P<0.05).5)TCM syndrome integral and curative effect?liver function: when treated for 12 weeks and 24 weeks,all the patients' TCM syndrome integral and curative effect,liver function were improved better than the comparison group,the difference was statistically significant(P<0.05);compared with the control group,the TCM syndrome integral and curative effect,liver function of the treatment group were improved better,the difference between the two groups was statistically significant(P<0.05).6)Safety evaluation: before and after treatment,there was no obvious abnormality in the two groups of patients in vital signs,blood routine,urine routine,stool routine,renal function,electrocardiogram.During the treatment,both the two groups of patients were not appeard serious adverse reaction and side effects.Conclusions: Dahuang and Zhechong pills combined with Entecavir in treating decompensated Hepatitis B cirrhosis of blood-stasis obstructing type has a good curative effect,and it's better than use simple Entecavir treatment.Dahuang and Zhechong pills combined with Entecavir can alleviate the symptoms of patients with blood-stasis obstruction and reduce the inflammation of liver.It also has definite therapeutic effect in resisting hepatic fibrosis,decreasing the portal venous diameter and the thickness of spleen and with high safety.To some extent,it can delay the process of liver cirrhosis.This treatment scheme shows the advantages and characteristics of the combination of Chinese and western medicine in treating liver disease.It is worthy to be popularized in clinic.